← Leaderboards
Stephen Goutman
University Of Michigan At Ann Arbor
$5,836,753
Attributed
$13,946,057
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.6M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,547,205 · 4
ATSDR$3,398,852 · 3
By mechanism
R01$12,436,796 · 5
K23$1,009,261 · 1
U01$500,000 · 1
Top collaborators
- Eva L Feldman11 shared
- Benjamin Joseph Murdock6 shared
- Stuart A Batterman5 shared
- Maureen Agnes Sartor5 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Eva L Feldman$26,770,746
- Suzanne E Judd$21,734,940
- Stuart A Batterman$13,600,215
- Richard A. Miller$53,224,142
- Sung Kyun Park$9,220,850
Others in their field
Other Emerging Leaders on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Beth Baseler · Leidos Biomedical Research, Inc.$91,415,673
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
Research focus
InsightAmyotrophic Lateral SclerosisPersonsInnovationRecording Of Previous EventsPublic HealthPhenotypeCohortMichiganAffectLinkGenesGeneticData SetAreaEnvironmental Risk FactorEpigenetic ProcessInflammationAmyotrophic Lateral Sclerosis TherapyEnvironmentBloodDisorder RiskImmuneCharacteristics
Grant awards (22)
Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis$3,133,754
R01 · FY2025 · ES
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$515,683
R01 · FY2025 · NS · contact PI
Spectral flow cytometry identifies new immune signatures that provide personalized ALS risk and progression biomarkers and therapeutic targets$500,000
U01 · FY2025 · TS · contact PI
RFA-TS-23-001: Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS)$500,000
R01 · FY2025 · TS · contact PI
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort$719,029
R01 · FY2024 · NS
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$568,145
R01 · FY2024 · NS · contact PI
RFA-TS-23-001: Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS)$500,000
R01 · FY2024 · TS · contact PI
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort$736,527
R01 · FY2023 · NS
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$613,303
R01 · FY2023 · NS · contact PI
Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS)$500,000
R01 · FY2023 · TS · contact PI
Linking long-term air pollution exposure with inflammation, ALS risk, and disease progression$499,206
R01 · FY2023 · TS
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort$984,329
R01 · FY2022 · NS
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$633,717
R01 · FY2022 · NS · contact PI
Linking long-term air pollution exposure with inflammation, ALS risk, and disease progression$499,206
R01 · FY2022 · TS
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort$989,984
R01 · FY2021 · NS
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$643,473
R01 · FY2021 · NS · contact PI
Linking long-term air pollution exposure with inflammation, ALS risk, and disease progression$400,440
R01 · FY2021 · TS
Impact of Geospatial Factors and Environmental Pollutants on Amyotrophic Lateral Sclerosis in the State of Michigan$202,076
K23 · FY2021 · ES · contact PI
Impact of Geospatial Factors and Environmental Pollutants on Amyotrophic Lateral Sclerosis in the State of Michigan$202,076
K23 · FY2020 · ES · contact PI
Impact of Geospatial Factors and Environmental Pollutants on Amyotrophic Lateral Sclerosis in the State of Michigan$201,789
K23 · FY2019 · ES · contact PI
Impact of Geospatial Factors and Environmental Pollutants on Amyotrophic Lateral Sclerosis in the State of Michigan$201,795
K23 · FY2018 · ES · contact PI
Impact of Geospatial Factors and Environmental Pollutants on Amyotrophic Lateral Sclerosis in the State of Michigan$201,525
K23 · FY2017 · ES · contact PI